Asthma and lower airway diseaseRecent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma
Section snippets
Study design
The methods and baseline cohort characteristics of the TENOR study have been previously described.8, 15 Briefly, TENOR was a prospective, observational, 3-year study (2001-2004) conducted in the United States in patients with severe difficult-to-treat asthma followed by asthma specialists. Patients were recruited from diverse geographic areas to represent typical patient care settings, including managed care organizations, community physicians/practices, and academic centers. No experimental
Baseline demographics and RSE
Of the 637 children age 6 to 11 years in the TENOR database, 68 did not have any follow-up data, and 6 others did not have follow-up visits during which HCU data were recorded, leaving data from 563 children available for analysis. Children excluded from the analysis were not appreciably different from those included in terms of age, physician-assessed asthma severity, and number of asthma control problems, but they were more likely to be girls (44.4% vs 31.3%; P = .025) and black (35.1% vs
Discussion
This study demonstrates a strong association between recent and future severe exacerbations in a large cohort of children with severe or difficult-to-treat asthma. This association persisted and remained strong (ORs ranged from 1.99 to 3.08) after adjusting for demographic and clinical variables, asthma control by the impairment domain, and allergic and nonallergic triggers, demonstrating that regardless of these other factors, RSE is the main driver of FSE in children with severe or
References (35)
- et al.
A comparison of the clinical characteristics of children and adults with severe asthma
Chest
(2003) - et al.
Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2007) - et al.
Severe asthma: an overview
J Allergy Clin Immunol
(2006) - et al.
Managing severe asthma
J Allergy Clin Immunol
(2006) - et al.
Severity, control, and responsiveness in asthma
J Allergy Clin Immunol
(2006) - et al.
Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma
Ann Allergy Asthma Immunol
(2004) - et al.
Recent asthma exacerbations: a key predictor of future exacerbations
Respir Med
(2007) - et al.
Predicting episodes of poor asthma control in treated patients with asthma
J Allergy Clin Immunol
(2006) - et al.
Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide
J Allergy Clin Immunol
(2006) - et al.
Asthma control and future asthma-related morbidity in inner-city asthmatic children
Ann Allergy Asthma Immunol
(2008)
Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma
J Allergy Clin Immunol
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial
J Allergy Clin Immunol
The public health implications of asthma
Bull World Health Organ
Summary health statistics for U.S. children: National Health Interview Survey, 2005
Vital Health Stat
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation
J Appl Physiol
Asthma in the United States: recent trends and current status
J Manag Care Pharm
Asthma severity and medical resource utilisation
Eur Respir J
Cited by (0)
Support for third-party medical writing assistance was provided by Genentech USA, Inc, and Novartis Pharmaceuticals Corp.
Disclosure of potential conflict of interest: T. Haselkorn is a consultant for Genentech. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from AstraZeneca, Merck, GlaxoSmithKline, TEVA, Aerocrine, and the National Heart, Lung, and Blood Institute. B. E. Chipps is an advisor and/or speakers' bureau member for Alcon, Aventis, Genentech, AstraZeneca, Boehringer, GlaxoSmithKline, MedPoint, Novartis, Pfizer, Schering, Sepracor, and Merck and has received support for research and/or educational activities from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPoint, Novartis, Schering, Sepracor, and Merck. D. R. Mink is an employee of ICON Clinical Research, which receives research funding from Genentech. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, and Merck and has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, Ross Pharmaceuticals, and GlaxoSmithKline. F. E. R. Simons has received research support from the Canadian Institutes of Health Research and has consulted for Genentech. M. Massanari is an employee of Novartis. J. E. Fish is an employee of Genentech.